TY - JOUR
T1 - The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space
AU - Klughammer, Johanna
AU - Kiesel, Barbara
AU - Roetzer, Thomas
AU - Fortelny, Nikolaus
AU - Nemc, Amelie
AU - Nenning, Karl-Heinz
AU - Furtner, Julia
AU - Sheffield, Nathan C
AU - Datlinger, Paul
AU - Peter, Nadine
AU - Nowosielski, Martha
AU - Augustin, Marco
AU - Mischkulnig, Mario
AU - Ströbel, Thomas
AU - Alpar, Donat
AU - Ergüner, Bekir
AU - Senekowitsch, Martin
AU - Moser, Patrizia
AU - Freyschlag, Christian F
AU - Kerschbaumer, Johannes
AU - Thomé, Claudius
AU - Grams, Astrid E
AU - Stockhammer, Günther
AU - Kitzwoegerer, Melitta
AU - Oberndorfer, Stefan
AU - Marhold, Franz
AU - Weis, Serge
AU - Trenkler, Johannes
AU - Buchroithner, Johanna
AU - Pichler, Josef
AU - Haybaeck, Johannes
AU - Krassnig, Stefanie
AU - Mahdy Ali, Kariem
AU - von Campe, Gord
AU - Payer, Franz
AU - Sherif, Camillo
AU - Preiser, Julius
AU - Hauser, Thomas
AU - Winkler, Peter A
AU - Kleindienst, Waltraud
AU - Würtz, Franz
AU - Brandner-Kokalj, Tanisa
AU - Stultschnig, Martin
AU - Schweiger, Stefan
AU - Dieckmann, Karin
AU - Preusser, Matthias
AU - Langs, Georg
AU - Baumann, Bernhard
AU - Knosp, Engelbert
AU - Widhalm, Georg
AU - Marosi, Christine
AU - Hainfellner, Johannes A
AU - Woehrer, Adelheid
AU - Bock, Christoph
N1 - Funding Information:
We thank all patients who have donated their samples for this study. We also thank G. Wilk, M. Muck, S. Schmid, and U. Andel for technical assistance with immunohistochemical stainings, macrodissection, and tumor tissue shavings; S. Mages for contributing to the interactive data visualization; the Biomedical Sequencing Facility at CeMM for assistance with next-generation sequencing; and all members of the Bock lab for their help and advice. The study was funded in part by an Austrian Science Fund grant (FWF KLI394) to A.W., a Marie Curie Career Integration Grant (European Union’s Seventh Framework Programme grant agreement no. PCIG12-GA-2012-333595) to C.B., an ERA-NET project grant (EpiMark FWF I 1575-B19) to C.B., an Austrian Science Fund grant (FWF I2714-B31) to G.L. and K.-H.N, and an ERC Starting Grant (European Union’s Horizon 2020 research and innovation programme, grant agreement no. 640396) to B.B. Moreover, C.B. is supported by a New Frontiers Group award of the Austrian Academy of Sciences and by an ERC Starting Grant (European Union’s Horizon 2020 research and innovation programme, grant agreement no. 679146). Activities of the Austrian Brain Tumor Registry are supported by unrestricted research grants of Roche Austria to J.A.H. and the Austrian Society of Neurology to S.O. Some of the samples used for this research project were kindly provided by Biobank Graz.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Glioblastoma is characterized by widespread genetic and transcriptional heterogeneity, yet little is known about the role of the epigenome in glioblastoma disease progression. Here, we present genome-scale maps of DNA methylation in matched primary and recurring glioblastoma tumors, using data from a highly annotated clinical cohort that was selected through a national patient registry. We demonstrate the feasibility of DNA methylation mapping in a large set of routinely collected FFPE samples, and we validate bisulfite sequencing as a multipurpose assay that allowed us to infer a range of different genetic, epigenetic, and transcriptional characteristics of the profiled tumor samples. On the basis of these data, we identified subtle differences between primary and recurring tumors, links between DNA methylation and the tumor microenvironment, and an association of epigenetic tumor heterogeneity with patient survival. In summary, this study establishes an open resource for dissecting DNA methylation heterogeneity in a genetically diverse and heterogeneous cancer, and it demonstrates the feasibility of integrating epigenomics, radiology, and digital pathology for a national cohort, thereby leveraging existing samples and data collected as part of routine clinical practice.
AB - Glioblastoma is characterized by widespread genetic and transcriptional heterogeneity, yet little is known about the role of the epigenome in glioblastoma disease progression. Here, we present genome-scale maps of DNA methylation in matched primary and recurring glioblastoma tumors, using data from a highly annotated clinical cohort that was selected through a national patient registry. We demonstrate the feasibility of DNA methylation mapping in a large set of routinely collected FFPE samples, and we validate bisulfite sequencing as a multipurpose assay that allowed us to infer a range of different genetic, epigenetic, and transcriptional characteristics of the profiled tumor samples. On the basis of these data, we identified subtle differences between primary and recurring tumors, links between DNA methylation and the tumor microenvironment, and an association of epigenetic tumor heterogeneity with patient survival. In summary, this study establishes an open resource for dissecting DNA methylation heterogeneity in a genetically diverse and heterogeneous cancer, and it demonstrates the feasibility of integrating epigenomics, radiology, and digital pathology for a national cohort, thereby leveraging existing samples and data collected as part of routine clinical practice.
KW - Chromosome Mapping
KW - DNA Methylation/genetics
KW - Disease Progression
KW - Epigenesis, Genetic
KW - Female
KW - Genetic Heterogeneity
KW - Genome, Human/genetics
KW - Glioblastoma/genetics
KW - High-Throughput Nucleotide Sequencing
KW - Humans
KW - Male
KW - Neoplasm Recurrence, Local/genetics
UR - http://www.scopus.com/inward/record.url?scp=85053049192&partnerID=8YFLogxK
U2 - 10.1038/s41591-018-0156-x
DO - 10.1038/s41591-018-0156-x
M3 - Journal article
C2 - 30150718
SN - 1078-8956
VL - 24
SP - 1611
EP - 1624
JO - Nature Medicine
JF - Nature Medicine
IS - 10
ER -